Medication Monitor

Generic Name (Trade Name—Company)
May 29, 2019


(Sorilux—Mayne Pharma Group)
Calcipotriene has new indication for adolescent plaque psoriasis

FDA has approved calcipotriene foam, 0.005%, for treating plaque psoriasis of the scalp and body in patients aged 12 years and older. Plaque psoriasis is the most common form of psoriasis, affecting roughly 80% of people who have the condition.

FDA approved calcipotriene in 2010 on the basis of evidence from two 8-week placebo-controlled clinical trials in patients with mild to moderate plaque psoriasis of the body and one 8-week placebo-controlled clinical trial in patients with moderate plaque psoriasis of the scalp. Further data were obtained in a follow-on open label study in patients aged 12 to 17 years with psoriasis. Calcipotriene is a synthetic vitamin D analog that has a similar receptor binding affinity as natural vitamin D. The exact mechanism of action contributing to the clinical efficacy is unknown.